Efesovir for hospitalized COVID-19 patients at high risk
Part of Infections, Lungs & breathing clinical trials.
This Phase 2 trial tests whether Efesovir can help treat COVID-19 in hospitalized adults who are at higher risk and whose symptoms started within the last 10 days. If you qualify, the study aims to see if the medicine improves recovery and safety compared with standard care.
Summary written for real people, not researchers, by Clin2.
Who can take part
- Be 18 to 59 years old and currently hospitalized with COVID-19 confirmed by PCR test
- Have been sick with COVID-19 for 10 days or less
- Be able to take the study medicine by mouth (not so confused that you can’t swallow pills/medicine)
- Not be pregnant or breastfeeding
- Agree to use reliable birth control methods during the study and sign informed consent
- Not be in another clinical trial now, and not have joined one in the last 2 months
Quick eligibility check
Answer a few plain-language questions, based on this study's own requirements, to get a preliminary sense of fit.
Similar studies
Other trials that look related to this one.
This early-stage study tests COVID-19 treatments in people who have recently developed symptoms and who test positive for the virus. It aims to find safer, more effective options for preventing worsening disease, especially in higher-risk groups.
This trial studies whether PF-07321332 (with ritonavir) helps children under 18 who have COVID-19 at home but are at high risk of severe illness. It looks at whether starting treatment early can reduce progression to worse disease.
This trial tests whether Codivir can help people hospitalized with moderate COVID-19 recover better than a placebo (inactive pill). It will compare outcomes while participants receive standard hospital care.
This trial looks at how well an antiviral works in the body when started early in people with COVID-19 symptoms. You may be able to join if you’re an otherwise healthy adult with confirmed infection and symptoms for less than 4 days.
This trial tests if a new medicine called ibuzatrelvir can help people with COVID-19 who have certain health risks avoid severe illness. It is for patients who cannot or choose not to take another COVID-19 pill called Paxlovid.
This trial tests a new antiviral pill, secutrelvir, for people with mild to moderate covid-19 who are at higher risk of getting seriously ill. It aims to see if the drug can prevent hospitalization or severe disease.
Hear when a new Covid19 trial opens
We’ll email you when one opens — at most once a week, no account needed, unsubscribe anytime.